Drug Profile

ALTA 2530

Alternative Names: ALTA2530; OSP-101

Latest Information Update: 18 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Bronchiolitis obliterans
New Molecular Entity Yes

06 Dec 2022 Altavant Sciences has been merged with Enzyvant to form Enzyvant
01 Apr 2022 Preclinical trials in Bronchiolitis Obliterans in USA (Inhalation)
18 Feb 2021 Altavant Sciences, Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases agree for the preclinical pilot study for Lung injuries

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com